Elan Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dublin Ireland (1969)
Status: Acquired by Perrigo (2013)

Organization Overview

First Clinical Trial
2001
NCT00027300
First Marketed Drug
2000
rimabotulinumtoxinB (Myobloc)
First NDA Approval
2001
frovatriptan (frova)
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Elan | ELAN PHARM

Indications

Approved Indications


 

Chronic Pain

Cluster Headache

Migraine with Aura

Migraine without Aura

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Alzheimer Disease (Phase 2)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Bipolar Disorder (Phase 4)

Cerebral Palsy (Phase 2)

Chronic Pain (Phase 3)

Crohn Disease (Phase 4)

Dementia (Phase 2)

Disease (Phase 2)

Down Syndrome (Phase 2)

Headache (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Immune Reconstitution Inflammatory Syndrome (Phase 4)

Leukoencephalopathies (Phase 4)

Leukoencephalopathy, Progressive Multifocal (Phase 4)

Migraine Disorders (Phase 2)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Muscle Spasticity (Phase 3)

Pneumonia (Phase 4)

Psychomotor Agitation (Phase 2)

Sclerosis (Phase 4)

Spinal Cord Injuries (Phase 3)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial APIs: 17